Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor ...

Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of ...

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama sheds light on the pharmaceuticals industry behind them ...

Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Following last month’s fatal shooting of an insurance executive, healthcare’s largest investor meeting has assumed a higher ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...

Eli Lilly said on Monday it would acquire cancer therapy developer Scorpion Therapeutics for $2.5 billion in cash.